Beste VJHemOnc podcasts (2024)

1
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs 43:51

5d ago43:51

43:51

In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help he…

1
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification 22:22

12d ago22:22

22:22

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field. In this week's podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, …

1
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors 13:02

19d ago13:02

13:02

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS). In this podcast, Uma Borate, MD, The Oh…

1
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception 9:39

25d ago9:39

9:39

Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment. In this podcast, Stephen Ansel…

1
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT 13:00

1M ago13:00

13:00

The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies explor…

1
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology 33:31

1M ago33:31

33:31

While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due to the highly varied presentation of this disease. As clinicians and researchers work to improve outcomes for patients, there is increasing importance being placed on the role of the multidisciplinary team in treating the…

1
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy 13:02

2M ago13:02

13:02

Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to im…

1
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks 12:58

2M ago12:58

12:58

The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today's episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discu…

1
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents 12:10

2M ago12:10

12:10

The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents. In this podcast, …

1
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 18:16

2M ago18:16

18:16

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS; HR-MDS). Treatment and management strategies vary for LR-MDS versus HR-MDS, and a number of challenges remain in the field. In this podcast, you will hear from leading experts who discuss several t…

1
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine 12:21

3M ago12:21

12:21

In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being evaluated in clinical trials, the future looks promising for patients. Despite these advances, there are challenges and unmet needs which remain, and both clinicians and researchers are working to addre…

1
Updates, challenges and novel agents being explored in BPDCN 9:49

3M ago9:49

9:49

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain in the diagnosis, treatment and management of this disease, with a lack of clinical trials in the field. However, clinicians and researchers are working to improve upon these unmet needs, …

1
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets 18:18

3M ago18:18

18:18

The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions. In this podcast, Moham…

1
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy 11:04

3M ago11:04

11:04

In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated. In this podcast, leading experts Rabi Hanna, M…

1
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis 10:29

3M ago10:29

10:29

In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients…

1
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF 17:12

4M ago17:12

17:12

The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made. At the 65th ASH Annu…

1
iwNHL 2023 Session V: Expanding the CAR platform in NHL 10:59

4M ago10:59

10:59

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials 20:50

4M ago20:50

20:50

The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL. Tune in as we share some key highlights from this year's meeting. In this podcast, a variety of topics are covered, including the role …

1
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies 15:34

5M ago15:34

15:34

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP 12:23

5M ago12:23

12:23

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients. In this podcast, Angela Di…

1
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL 16:08

5M ago16:08

16:08

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches 12:57

5M ago12:57

12:57

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diag…

1
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma 14:37

6M ago14:37

14:37

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma 13:52

6M ago13:52

13:52

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes 14:41

6M ago14:41

14:41

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…

1
Classifying frailty and approaching elderly patients with lymphoma 11:11

6M ago11:11

11:11

While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several challenges associated with treating elderly patients in these disease settings. The presence of comorbidities, as well as the risk of treatment-related toxicities, makes the treatment of elderly patients an important area…

1
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS 19:04

6M ago19:04

19:04

The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being conducted with the goal of improving the understanding of this disease. Furthermore, there have been recent updates to classification systems for MDS, including the Molecular International Prognostic Sco…

1
iwAL 2023 Session III: The relevance of TP53 mutation in AML 9:55

7M ago9:55

9:55

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…

1
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more 28:06

7M ago28:06

28:06

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…

1
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics 18:04

7M ago18:04

18:04

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeti…

1
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions 10:51

7M ago10:51

10:51

Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased in recent years. MRD can indicate the depth of response to treatment as well as patient outcomes, leading to suggestions of using MRD status to guide the treatment of patients with myeloma. In this pod…

1
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL 9:17

8M ago9:17

9:17

The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the introduction of immunotherapies including CAR-T cells and bispecific antibodies has provided hope for several patients. While both CAR-T cells and bispecific antibodies have their benefits, there are s…

1
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions 10:05

8M ago10:05

10:05

Myelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years, there has been an increased interest in understanding various pre-MDS states, including idiopathic cytopenia of unknown significance (ICUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal c…

1
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored 8:17

8M ago8:17

8:17

Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including ASXL1, EZH2, and TP53, are involved in progression to MPN-AP/BP, and there are a number of challenges with treating patients who progress to this stage. In this podcast, …

1
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma 7:07

9M ago7:07

7:07

Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents. In this podcast, experts Salomon Manie…

1
Overcoming barriers to CAR-T therapy: improving access and cost 11:26

9M ago11:26

11:26

CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals with a high unmet medical need. Although CAR-T cells have demonstrated promising efficacy in patients, there are several challenges that need to be overcome before these are optimally used i…

1
The importance of addressing quality of life and improving symptom management in MPNs 6:14

9M ago6:14

6:14

Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which negatively impact their quality of life (QoL). Novel agents, including JAK inhibitors, have demonstrated an ability to reduce symptom burden in patients with MPNs, and there is ongoing research aimed at i…

1
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team 8:29

9M ago8:29

8:29

Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage. The diagnosis and treatment of this disease remain a major challenge, with several novel agents being explored in clinical trials. Furthermore, clinicians and researchers are drawing attention to the important role of the…

1
Hemophilia: the current standard of care and the value of novel gene therapies 6:46

10M ago6:46

6:46

Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor replacement therapy has been the standard of care in hemophilia, although there are limitations to this approach. More recently, the approval of novel gene therapies has presented a promising option for pa…

1
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors 14:14

10M ago14:14

14:14

Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent agents being explored. There are several questions surrounding the sequencing and selection of these agents, and clinical trials exploring their efficacy. At the 2023 EHA meeting, leading expe…

1
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice 8:23

10M ago8:23

8:23

In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients with relapsed/refractory (R/R) disease. Several clinical trials are evaluating the efficacy of CAR-T cells and are further exploring the possibility of bringing these agents into earlier lines of therapy. At the 2023 EH…

1
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management 16:47

10M ago16:47

16:47

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and CAR-T cells demonstrating promising results. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology. In thi…

1
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials 12:40

10M ago12:40

12:40

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in …

1
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease 11:01

11M ago11:01

11:01

Therapeutic agents for patients with myelodysplastic syndromes (MDS) are currently under active investigation in clinical trials. The management of cytopenias, including anemia, is an important component in the treatment of lower-risk MDS (LR-MDS), and many agents are being evaluated to better manage these. In the context of higher-risk MDS (HR-MDS…

1
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes 11:04

11M ago11:04

11:04

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in …

1
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks 14:28

11M ago14:28

14:28

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in …

1
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies 15:18

11M ago15:18

15:18

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in …

1
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed 10:59

12M ago10:59

10:59

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s mee…

1
The current role of stem cell transplantation in MPNs & how this may change with novel agents 9:48

12M ago9:48

9:48

Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several advances in the MPN treatment landscape, allogeneic stem cell transplantation (alloSCT) remains the only curative option for patients. There are several important factors to consider when selecting patient…

1
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies 11:22

12M ago11:22

11:22

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s mee…

Podcasts die het beluisteren waard zijn

VJHemOnc Podcasts

Podcasts die het beluisteren waard zijn

Korte handleiding